Fig. 3: In vitro cytotoxicity evaluation of 20D9h3-DUBA in comparison to 20D9h3-MMAF. | Leukemia

Fig. 3: In vitro cytotoxicity evaluation of 20D9h3-DUBA in comparison to 20D9h3-MMAF.

From: Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates

Fig. 3

MOLM-13 (FLT3-positive, A), MV4-11 (FLT3-positive, B) and HL-60 (FLT3-negative, C) cells were treated with a dilution row of 20D9h3-mAb, 20D9h3-DUBA, 20D9h3-MMAF, IgG1-DUBA or IgG1-MMAF for 96 h. Viable cells were assessed by resazurin readout and normalized to untreated control. mean±s.d; n = 3 biological replicates. D Ba/F3-pMIY cells expressing ev, hFLT3low, hFLT3medium or hFLT3high were treated with different concentrations of 20D9h3-DUBA for 72 h. Viable cells were assessed by trypan blue exclusion and normalized to untreated control. mean±s.d.; n = 3 biological replicates. Ba/F3-pMIY cells expressing ev (E), hFLT3high (F), FcγRI (G) or hFLT3+FcγRI (H) were treated with a dilution row of 20D9h3-DUBA, 20D9h3-LALA-DUBA, IgG1-DUBA or IgG1-LALA-DUBA for 72 h. Viable cells were assessed by flow cytometry using LIVE/DEAD fixable far red dead cell stain and normalized to untreated control. mean±s.d.; n = 3 biological replicates.

Back to article page